Neurology

#Biopharma #Business #Neurology

Relief Therapeutics and NeuroX to combine in new company 

Biotechnology company Relief Therapeutics has announced a business combination with commercial-stage company NeuroX to create a new digital neurotherapeutics company.  The business combination follows approval from Relief’s shareholders, who have also approved a capital increase through the issuance of 140 million new ordinary shares.   The business combination is expected to close in December… Read More

#Business & Investment #News

MRI of the brain
#CDMO #epilepsy #Neurology

Neumirna and ten23 partner to advance epilepsy treatments

Biotechnology company Neumirna Therapeutics has announced its partnership with CDMO company ten23 health to advance treatments for epilepsy and other neurological diseases.  The companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring… Read More

#News

Human brain
#Biomarkers #Drug discovery #Neurology #Neuroscience #Whitepaper

Navigating neurological biomarker research: Download the Whitepaper

Neurological biomarker research is advancing rapidly, but key challenges remain. Download this new Whitepaper from Olink entitled ‘Navigating neurological biomarker research: Progress, learnings and future directions’. The Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A… Read More

#News

#Biomarkers #Drug discovery #Neurology #Neuroscience #Whitepaper

Navigating neurological biomarker research: Progress, learnings and future directions

Neurological biomarker research is advancing rapidly, but key challenges remain. This Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Read More

#Resources #Whitepapers

Immunotherapy
#Autoimmune disease #Immunic Therapeutics #Immunology #MS #Neurodegenerative disorders #Neurology

Moving beyond managing autoimmune diseases to progression

What if we’re finally moving beyond managing autoimmune diseases and toward slowing their progression? That’s the promise behind Immunic Therapeutics' recent long-term data on vidofludimus calcium (IMU‑838. Dr Daniel Vitt, CEO of Immunic, discusses these results and insights with DDW’s Megan Thomas. MT: Can you unpack what the sustained neuroprotective… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Alzheimer's #CNS #Gene editing #Human disease models #Interview #Neurodegenerative disorders #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife #Stem cells

Podcast: Unlocking neuroscience drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More

#News

Neurones in the brain
#Alzheimer's #Cell and gene therapy #Cognitive impairment #Gene therapy #Neurology #Neuroscience #University of California San Diego

Alzheimer’s gene therapy shows promise in preserving brain function

Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease (AD) that could help protect the brain from damage and preserve cognitive function. Unlike existing treatments for AD that target unhealthy protein deposits in the brain, the new approach could help address… Read More

#News

Human neuron
#Augustine Therapeutics #Charcot-Marie-Tooth disease (CMT) #Clinical trials #Neurology #Neuroscience

First patient dosed with Charcot-Marie-Tooth disease treatment

Augustine Therapeutics has dosed the first patient in its Phase I clinical trial evaluating lead candidate AGT-100216, the first peripherally-restricted, selective cytosolic Histone DeACetylase 6 (HDAC6) inhibitor for the treatment of Charcot-Marie-Tooth disease (CMT), an inherited neurological disorder that affects the peripheral nerves responsible for transmitting signals between the brain,… Read More

#News

#Alzheimer's #Mergers and acquisitions #Neurodegenerative disorders #Neurology #Neuroscience #Sanofi

Sanofi expands neurology pipeline with Vigil Neuroscience acquisition

Sanofi has entered into an agreement to acquire Vigil Neuroscience, a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.  The company says this acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances its early-stage pipeline and includes VG-3927, which will be evaluated… Read More

#Business & Investment #News #Trending News

Neurons
#AAV #BlackfinBio #FDA #Gene therapy #Neurology #Orphan drugs #Paediatrics #Rare disease

FDA clears gene therapy trial for rare neurological disease

The US Food and Drug Administration (FDA) has cleared BlackfinBio’s Investigational New Drug (IND) application for a Phase I/II clinical trial of novel adeno-associated virus (AAV) gene therapy, BFB-101, in children with Hereditary Spastic Paraplegia Type 47 (SPG47).  The trial will be conducted in the US at Boston Children’s Hospital… Read More

#News #Regulatory

FDA
#FDA #Neurology #Rare disease #Recordati

FDA grants label expansion for Cushing’s disease treatment

The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia.  It is now approved in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.   This is an expansion of… Read More

#News #Regulatory

Neurons
#Cell therapy #GPCRs #Neurology #Neuroscience #Stanford University

New ‘PAGER’ technology could transform cell therapies

Researchers at Stanford University have built a new synthetic receptor with broad potential to programme cell activity, including immune response and neurological signalling.  Detailed in a paper published in Nature, the new synthetic receptor accommodates a broader range of inputs and… Read More

#Editor's Choice #News

Brain physiology
#Amyotrophic lateral sclerosis (ALS) #Artificial intelligence (AI) #Longitude Prize #Machine learning #Motor neuron disease #Neurology #Neuroscience

Third global Longitude Prize to be launched in 2025 focusing on ALS

The Longitude Prize series from Challenge Works will launch the Longitude Prize on amyotrophic lateral sclerosis (ALS) in Spring 2025. The next installment in the prize series follows the success of the Longitude Prize on antimicrobial resistance (AMR), won in 2024 by Sysmex Astrego’s PA-100 AST system, and the Longitude… Read More

#News

Gene therapy
#FDA #Gene therapy #Neurology #Neuroscience #PTC Therapeutics #Rare disease

FDA approves first gene therapy for rare genetic disorder

The US Food and Drug Administration (FDA) has approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy for the treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters,… Read More

#News #Regulatory

#AAV #Collaboration #Dyno Therapeutics #Gene therapy #Neurology #Roche

Roche and Dyno advance AAV gene therapies for neurological diseases

Dyno Therapeutics and Roche have announced a second research collaboration to develop adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. Dyno and Roche previously agreed a research collaboration and license agreement for neurological diseases and liver-directed therapies in October 2020. Under the terms of this new collaboration, Dyno… Read More

#Business & Investment #News

Neuron
#Neurology #Neuroscience #Precision medicine #Psychiatry #Webinar

Watch now! DDW Neuroscience Showcase

In this free online event hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase includes a panel discussion looking at the use of new drug discovery… Read More

#News